Head-to-head · WeighScore
NuuVim vs PlexusDx
The verdict
NuuVim takes it — 71.1/100 to 67.7/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | PlexusDx |
|---|---|---|
| WeighScore | 71.1/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #100 | #161 |
| Semaglutide | $79/mo (all doses, compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | $133/mo (all doses, compounded) | $249/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #100 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #161 · C
Strengths
- Licensed providers available in all 50 states
- Range of options including low-cost microdose GLP-1 from $129/mo
- Optional Precision Peptide genetic panel adds a personalization angle
- Independent clinician review via state-licensed telehealth platform
- Compounded medications from state-licensed pharmacies
Where it loses points
- Compounded medications only; no FDA-approved brand options
- Specific compounding pharmacies not named
- Genetic-panel upsell may not add clinical value for everyone
- Tirzepatide pricing from $249/mo is higher than budget rivals
- No insurance accepted
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.